Literature DB >> 3668390

Studies of the pathogenesis of Gaucher's disease: tissue distribution and biliary excretion of [14C]L-glucosylceramide in rats.

T Tokoro1, A E Gal, L L Gallo, R O Brady.   

Abstract

The time course of the clearance from the blood and the tissue localization of [14C]L-glucosylceramide, a nonmetabolizable enantiomorph of D-glucosylceramide that accumulates in Gaucher's disease, has been determined. 14C-labeled L-glucosylceramide injected intravenously in the form of micelles or liposomes is rapidly removed from the circulation. Most of this lipid is taken up by the liver where it is found in both hepatocytes and nonparenchymal cells. This sphingolipid analog is promptly cleared from hepatocytes and a significant portion is recovered in the bile. The clearance of [14C]L-glucosylceramide from Kupffer cells is greatly prolonged in comparison with its brief residence in hepatocytes. These findings have significant implications regarding the pathogenesis and treatment of Gaucher's disease.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3668390

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  5 in total

1.  Glucosylceramide and lysophosphatidylcholines as potential blood biomarkers for drug-induced hepatic phospholipidosis.

Authors:  Kosuke Saito; Keiko Maekawa; Masaki Ishikawa; Yuya Senoo; Masayo Urata; Mayumi Murayama; Noriyuki Nakatsu; Hiroshi Yamada; Yoshiro Saito
Journal:  Toxicol Sci       Date:  2014-06-30       Impact factor: 4.849

2.  Recycling of glucosylceramide and sphingosine for the biosynthesis of gangliosides and sphingomyelin in rat liver.

Authors:  M Trinchera; R Ghidoni; S Sonnino; G Tettamanti
Journal:  Biochem J       Date:  1990-09-15       Impact factor: 3.857

3.  Stimulation of liver growth and DNA synthesis by glucosylceramide.

Authors:  S C Datta; N S Radin
Journal:  Lipids       Date:  1988-05       Impact factor: 1.880

4.  High incidence of cholesterol gallstone disease in type 1 Gaucher disease: characterizing the biliary phenotype of type 1 Gaucher disease.

Authors:  Tamar H Taddei; James Dziura; Shu Chen; Ruhua Yang; Hideyuki Hyogo; Cameron Sullards; David E Cohen; Gregory Pastores; Pramod K Mistry
Journal:  J Inherit Metab Dis       Date:  2010-03-31       Impact factor: 4.982

Review 5.  Developments in the treatment of Fabry disease.

Authors:  Sanne J van der Veen; Carla E M Hollak; André B P van Kuilenburg; Mirjam Langeveld
Journal:  J Inherit Metab Dis       Date:  2020-03-02       Impact factor: 4.982

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.